Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma

Modern Pathology

Volumn 27, Issue 10, 2014, Pages 1321-1330

  Koopmans, Anna E ^a   Verdijk, Robert M ^a   Brouwer, Rutger W W ^a   Van Den Bosch, Thierry P P ^a   Van Den Berg, Mike M P ^a   Vaarwater, Jolanda ^a   Kockx, Christel E M ^a   Paridaens, Dion ^b   Naus, Nicole C ^a   Nellist, Mark ^a   Van Ijcken, Wilfred F J ^a   Kiliç, Emine ^a   De Klein, Annelies ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM EYE HOSPITAL   (Netherlands)

Author keywords

BAP1; Genetics; Immunohistochemistry; Prognosis; Sequencing; Survival; Uveal melanoma

Indexed keywords

BRCA1 ASSOCIATED PROTEIN 1; CARRIER PROTEINS AND BINDING PROTEINS; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CHOROID TUMOR; CHROMOSOMAL PARAMETERS; CHROMOSOME 1P; CHROMOSOME 3; CHROMOSOME 3P; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CILIARY BODY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISOMY; ENUCLEATION; EPITHELIOID CELL; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; GENE DOSAGE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC UVEA MELANOMA; MISSENSE MUTATION; MUTATION RATE; NONSENSE MUTATION; POLYPLOIDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TETRAPLOIDY; TRIPLOIDY; TUMOR INVASION; TUMOR LOCALIZATION; UVEA MELANOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS;

EID: 84930352872     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.43     Document Type: Article

References (33)

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011;118:1881-1885.
2. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J 2012;18:148-152.
3. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci 2005;46:2253-2257.
4. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347:1222-1225.
5. Sisley K, Parsons MA, Garnham J, et al. Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer 2000;82:330-338.
6. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19:22-28.
7. White VA, Chambers JD, Courtright PD, et al. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998;83:354-359.
8. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-1413.
9. Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci 2006;47:3703-3707.
10. Nishikawa H, Wu W, Koike A, et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 2009;69:111-119.
11. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921.
12. Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-1112.
13. Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008;68:6953-6962.
14. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48:856-859.
15. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-672.
16. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PloS one 2012;7:e35295.
17. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-759.
18. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-1025.
19. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-1021.
20. Aoude LG, Vajdic CM, Kricker A, et al. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res 2013;26:278-279.
21. Naus NC, Verhoeven AC, van Drunen E, et al. Detection of genetic prognostic markers in uveal melanoma biopsies using fluorescence in situ hybridization. Clin Cancer Res 2002;8:534-539.
22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-1760.
23. Brouwer RW, van den Hout MC, Grosveld FG, et al. NARWHAL, a primary analysis pipeline for NGS data. Bioinformatics 2012;28:284-285.
24. McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-1303.
25. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078-2079.
26. Malignant melanoma of the uveaIn: Edge SD, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A (eds) . AJCC Cancer Staging Manual, 7th edn. Springer: New York; 2010, pp 547-559.
27. Rohlin A, Wernersson J, Engwall Y, et al. Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques. Hum Mutat 2009;30:1012-1020.
28. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;103:868-874.
29. Seddon JM, Gragoudas ES, Albert DM, et al. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol 1985;99:282-290.
30. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990;97:769-777.
31. Matatall KA, Agapova OA, Onken MD, et al. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer 2013;13:371.
32. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012;18:408-416.
33. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 2011;60:3-11.